Yvonne Curran, MD
Vascular Neurology · Chicago, ILNPI 1518950039
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $21,500 of the $25,948 with a category attached, or 82.9%. Teva Pharmaceuticals USA, Inc. accounts for 66.1% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2019 at $8,498 and has fallen 98.3% since, to $147 in 2025.
Across 118 payments — averaging $219.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$17K
- Lilly USA, LLC$7K
- AbbVie$554
- Pfizer$271
- Biohaven Pharmaceuticals, Inc.$199
- Novartis$125
- plus $360 from 5 others
What the payments were for
- Consulting fees$1,1504%
- Speaking & faculty fees$21,50083%
- Grants$420%
- Travel & lodging$5262%
- Food & beverage$2,66110%
- Education$700%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 31 | $17,146 |
| Lilly USA, LLC | 20 | $7,292 |
| AbbVie(2 entities) | 30 | $554 |
| Pfizer | 10 | $271 |
| Biohaven Pharmaceuticals, Inc. | 10 | $199 |
| Novartis | 6 | $125 |
| Boston Scientific | 1 | $114 |
| Stryker | 1 | $76 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $61 |
| Amgen | 3 | $57 |
| AstraZeneca | 3 | $53 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$25,948 in reported general payments places this provider in the 80th percentile of 32 vascular neurology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Nurtec OdtRimegepant Sulfate | 57 | $103,864 |
| Aimovig AutoinjectorErenumab-Aooe | 53 | $39,128 |
| UbrelvyUbrogepant | 30 | $36,500 |
| Ajovy SyringeFremanezumab-Vfrm | 20 | $33,547 |
| EliquisApixaban | 39 | $27,747 |
| Emgality PenGalcanezumab-Gnlm | 20 | $25,227 |
| Emgality SyringeGalcanezumab-Gnlm | 13 | $17,160 |
| BrilintaTicagrelor | 14 | $8,929 |
| LamictalLamotrigine | 11 | $8,408 |
| Gabapentin | 165 | $3,851 |
| Sumatriptan Succinate | 53 | $1,164 |
| Eletriptan HbrEletriptan Hydrobromide | 22 | $1,129 |
| Topiramate | 40 | $1,127 |
| RizatriptanRizatriptan Benzoate | 20 | $637 |
| Nortriptyline Hcl | 41 | $586 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerNurtec Odt, Eliquis | $271 | $131,61296 claims |
| AbbVieUbrelvy | $554 | $36,50030 claims |
| AstraZenecaBrilinta | $53 | $8,92914 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 32 vascular neurology providers in Illinois.
Other vascular neurology in Chicago
- Tareq Kass-HoutChicago$336K
- Phillip GorelickChicago$269K
- Richard BernsteinChicago$114K
- Fan CaprioChicago$9K
- Lesli SkolarusChicago$8K
- Monika ManchandaChicago$2K
- Sebastian UrdayChicago$1K
- Aisha AliChicago$640
- Silvya SotoChicago$349
- Gabriela TrifanChicago$126
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.